Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9347.026 | 0.9325 | 0.8950 | 1.2965 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9347.026 | 0.9281 | 0.8881 | 1.2965 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9347.026 | 0.9146 | 0.8669 | 1.2965 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9347.026 | 0.9653 | 0.9463 | 1.2965 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9347.026 | 0.9799 | 0.9689 | 1.2965 | |
| HCC1569 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9347.026 | 0.8160 | 0.7097 | 1.2965 | |
| HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9376.026 | 0.9886 | 0.9864 | 1.6827 | |
| HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9376.026 | 1.0685 | 1.0803 | 1.6827 | |
| HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9376.026 | 1.0931 | 1.1087 | 1.6827 | |
| HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9376.026 | 0.9908 | 0.9891 | 1.6827 | |
| HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9376.026 | 1.0041 | 1.0048 | 1.6827 | |
| HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9376.026 | 1.0242 | 1.0286 | 1.6827 | |
| HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9376.026 | 1.0498 | 1.0587 | 1.6827 | |
| HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9376.026 | 1.0661 | 1.0776 | 1.6827 | |
| HCC1806 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9376.026 | 0.9496 | 0.9395 | 1.6827 | |
| HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9386.026 | 1.0020 | 1.0026 | 1.5583 | |
| HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9386.026 | 0.9194 | 0.8950 | 1.5583 | |
| HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9386.026 | 1.0632 | 1.0802 | 1.5583 | |
| HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9386.026 | 0.8918 | 0.8583 | 1.5583 | |
| HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9386.026 | 0.9195 | 0.8951 | 1.5583 | |
| HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9386.026 | 0.8552 | 0.8090 | 1.5583 | |
| HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9386.026 | 0.9299 | 0.9089 | 1.5583 | |
| HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9386.026 | 0.9547 | 0.9414 | 1.5583 | |
| HCC1954 | HER2amp | Basal A | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9386.026 | 0.8144 | 0.7531 | 1.5583 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9469.026 | 0.9473 | 0.9125 | 1.2092 |